162 related articles for article (PubMed ID: 32461792)
1. Angiogenesis and Minimal Residual Disease in Patients with Acute Myeloid Leukemia.
Nematollahi P; Baradaran A; Kasaei Koopaei Z; Sajjadieh H
Int J Hematol Oncol Stem Cell Res; 2020 Apr; 14(2):93-98. PubMed ID: 32461792
[No Abstract] [Full Text] [Related]
2. Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): therapy induced changes and effects on survival.
Kuzu I; Beksac M; Arat M; Celebi H; Elhan AH; Erekul S
Leuk Lymphoma; 2004 Jun; 45(6):1185-90. PubMed ID: 15359999
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers of angiogenesis as prognostic factors in myelodysplastic syndrome patients treated with hypomethylating agents.
Kim CK; Han DH; Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Lee KT; Won JH; Hong DS; Kim HK
Leuk Res; 2016 Nov; 50():21-28. PubMed ID: 27639703
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
[TBL] [Abstract][Full Text] [Related]
5. Levels of bone marrow microvessel density are crucial for evaluating the status of acute myeloid leukemia.
Song Y; Tan Y; Liu L; Wang Q; Zhu J; Liu M
Oncol Lett; 2015 Jul; 10(1):211-215. PubMed ID: 26171001
[TBL] [Abstract][Full Text] [Related]
6. Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow.
Kern W; Danhauser-Riedl S; Ratei R; Schnittger S; Schoch C; Kolb HJ; Ludwig WD; Hiddemann W; Haferlach T
Haematologica; 2003 Jun; 88(6):646-53. PubMed ID: 12801840
[TBL] [Abstract][Full Text] [Related]
7. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
Zelezníková T; Babusíková O
Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
[TBL] [Abstract][Full Text] [Related]
8. [Change of vascular endothelial growth factor and its receptors expression in acute myeloid leukemia before and after treatment].
Zhang JQ; Wang JK; Li YM
Zhonghua Xue Ye Xue Za Zhi; 2004 Feb; 25(2):100-2. PubMed ID: 14990052
[TBL] [Abstract][Full Text] [Related]
9. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
[TBL] [Abstract][Full Text] [Related]
10. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow microvessel density and its prognostic significance in AML.
Rabitsch W; Sperr WR; Lechner K; Chott A; Prinz E; Valent P; Kalhs P
Leuk Lymphoma; 2004 Jul; 45(7):1369-73. PubMed ID: 15359635
[TBL] [Abstract][Full Text] [Related]
12. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
[TBL] [Abstract][Full Text] [Related]
13. Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort.
Brune MM; Stüssi G; Lundberg P; Vela V; Heim D; Manz MG; Haralambieva E; Pabst T; Banz Y; Bargetzi M; Grobholz R; Fehr M; Cogliatti S; Ossenkoppele GJ; Löwenberg B; Rudolf CB; Li Q; Passweg J; Mazzuchelli L; Medinger M; Tzankov A;
Ann Hematol; 2021 May; 100(5):1169-1179. PubMed ID: 33704530
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic Analysis of Minimal Residual Disease from Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplant by Flow Cytometry].
Hao Q; Zhang SQ; Zhang DM; Wang JB; Zhao J; Cheng HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):239-244. PubMed ID: 29397851
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
[TBL] [Abstract][Full Text] [Related]
16. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia.
Zhang R; Yang JY; Sun HQ; Jia H; Liao J; Shi YJ; Li G
Eur Rev Med Pharmacol Sci; 2015; 19(14):2679-88. PubMed ID: 26221900
[TBL] [Abstract][Full Text] [Related]
17. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.
Zeijlemaker W; Kelder A; Oussoren-Brockhoff YJ; Scholten WJ; Snel AN; Veldhuizen D; Cloos J; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2016 Mar; 30(3):708-15. PubMed ID: 26373238
[TBL] [Abstract][Full Text] [Related]
18. Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia.
Sun H; Li Y; Zhang ZF; Ju Y; Li L; Zhang BC; Liu B
Int J Hematol; 2015 Nov; 102(5):579-86. PubMed ID: 26358057
[TBL] [Abstract][Full Text] [Related]
19. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
Ravandi F; Jorgensen J; Borthakur G; Jabbour E; Kadia T; Pierce S; Brandt M; Wang S; Konoplev S; Wang X; Huang X; Daver N; DiNardo C; Andreeff M; Konopleva M; Estrov Z; Garcia-Manero G; Cortes J; Kantarjian H
Cancer; 2017 Feb; 123(3):426-435. PubMed ID: 27657543
[TBL] [Abstract][Full Text] [Related]
20. Universal monitoring of minimal residual disease in acute myeloid leukemia.
Coustan-Smith E; Song G; Shurtleff S; Yeoh AE; Chng WJ; Chen SP; Rubnitz JE; Pui CH; Downing JR; Campana D
JCI Insight; 2018 May; 3(9):. PubMed ID: 29720577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
